RYTM Q2 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+112.0% YoY

Gross Profit

$17M88.4% margin

Operating Income

-$47M-242.5% margin

Net Income

-$47M-243.0% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

+67.6%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$42M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$310M

Total Liabilities

$128M

Stockholders' Equity

$182M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$9M	+112.0%
Gross Profit	$17M	$9M	+95.5%
Operating Income	-$47M	-$45M	-3.3%
Net Income	-$47M	-$45M	-3.8%

Revenue Segments

Product revenue

$19M100%